Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar;39(3):573-579.
doi: 10.1007/s10815-022-02429-9. Epub 2022 Feb 14.

The use of metformin in women with polycystic ovary syndrome: an updated review

Adriana Leal Griz Notaro  1 , Filipe Tenorio Lira Neto  2
Affiliations
Review

The use of metformin in women with polycystic ovary syndrome: an updated review

Adriana Leal Griz Notaro et al. J Assist Reprod Genet. 2022 Mar.

Abstract

Purposes: Polycystic ovary syndrome (PCOS) is a major cause of female infertility, being present in up to 20% of women of childbearing age. Insulin resistance (IR) plays an important role in the pathophysiology of PCOS; therefore, its treatment may benefit women with the syndrome. The main drug used for IR management is metformin (MT). We aim to review the literature on the use of metformin in women with PCOS.

Methods: Using the terms "metformin" and "polycystic ovary syndrome," we conducted a search the PubMed, EMBASE, and Google Scholar databases. The research was restricted to articles published in English. Initially, only published meta-analyses were included, in the absence of meta-analyzes, RCT and well-designed prospective studies were used.

Results: Metformin increases success rates and decreases complication rates when used as an adjunctive medication for ovulation induction during low complexity assisted reproduction treatments and during ovarian stimulation for in vitro fertilization in women with PCOS. Evidence about the effect of metformin on fetal and obstetric complication rates is conflicting. Metformin is associated with high incidence of gastrointestinal symptoms; however, serious adverse effects are rare and there is no evidence of teratogenicity.

Conclusion: For women with PCOS, metformin is a good adjunctive medication for ovulation induction/stimulation for high and low complexity assisted reproduction therapies. The adverse effects are mostly mild, and there is no risk of teratogenicity, but the risk of long-term complications for the offspring is not yet defined. High heterogeneity of the studies limits extrapolation of findings, and further research is needed to determine which women will benefit most from the medication.

Keywords: Anovulation; Fertility; Insulin resistance; Ovulation induction; PCOS.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

References

    1. Bozdag G, et al. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2016;31(12):2841–2855. doi: 10.1093/humrep/dew218. - DOI - PubMed
    1. March WA, et al. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod. 2010;25(2):544–551. doi: 10.1093/humrep/dep399. - DOI - PubMed
    1. Azziz R. Polycystic Ovary syndrome. Obstet Gynecol. 2018;132(2):321–336. doi: 10.1097/AOG.0000000000002698. - DOI - PubMed
    1. Yildiz BO, et al. Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Hum Reprod. 2012;27(10):3067–3073. doi: 10.1093/humrep/des232. - DOI - PubMed
    1. Goldzieher JW, Axelrod LR. Clinical and biochemical features of polycystic ovarian disease. Fertil Steril. 1963;14:631–653. doi: 10.1016/S0015-0282(16)35047-6. - DOI - PubMed